PHARMACEUTICAL COMBINATION BASED ON PRMT5 INHIBITORS Russian patent published in 2024 - IPC A61K31/4439 A61K31/454 A61K31/502 A61K31/5025 A61K31/506 A61K31/517 A61K31/519 A61K31/5377 A61K31/55 A61P35/00 

FIELD: medicine; pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics, namely to a pharmaceutical composition for treating cancer. Pharmaceutical combination for treating cancer in a subject is selected from: (a) compounds (1S,2R,5R)-3-(2-(2-amino-3-chloro-5-fluoroquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopent-3-ene-1,2-diol (compound 24) or a pharmaceutically acceptable salt thereof and afatinib; (b) compounds (1S,2R,5R)-3-(2-(2-amino-3-chloro-5-fluoroquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopent-3-ene-1,2-diol (compound 24) or a pharmaceutically acceptable salt thereof and BI-3406; (c) compounds (1S,2R,5R)-3-(2-(2-amino-3-chloro-5-fluoroquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopent-3-ene-1,2-diol (compound 24) or a pharmaceutically acceptable salt thereof and ulixertinib.

EFFECT: above described combinations have a synergistic effect in treating cancer in a subject.

2 cl, 10 dwg, 5 ex